Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Masimo Co. (NASDAQ:MASI)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Masimo Co. (NASDAQ:MASI) by 27.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,513 shares of the medical equipment provider’s stock after purchasing an additional 6,715 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Masimo were worth $3,694,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Caisse DE Depot ET Placement DU Quebec purchased a new position in Masimo during the first quarter worth about $37,000. Massmutual Trust Co. FSB ADV increased its holdings in Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares in the last quarter. Belpointe Asset Management LLC increased its holdings in Masimo by 31.4% in the first quarter. Belpointe Asset Management LLC now owns 339 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 81 shares in the last quarter. DHJJ Financial Advisors Ltd. purchased a new position in Masimo in the third quarter valued at about $32,000. Finally, Castleview Partners LLC purchased a new position in Masimo in the first quarter valued at about $69,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler increased their target price on shares of Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a report on Monday, February 26th. Stifel Nicolaus raised shares of Masimo from a “hold” rating to a “buy” rating and increased their target price for the company from $148.00 to $170.00 in a report on Monday. Needham & Company LLC cut shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Jefferies Financial Group reissued a “hold” rating and set a $121.00 price objective (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. Finally, Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $117.00 to $160.00 in a research note on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $137.43.

Masimo Trading Up 0.1 %

Shares of MASI opened at $138.18 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.22. The firm has a 50 day simple moving average of $135.58 and a 200-day simple moving average of $113.53. Masimo Co. has a 1-year low of $75.22 and a 1-year high of $198.00. The stock has a market cap of $7.31 billion, a price-to-earnings ratio of 91.39 and a beta of 0.97.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The firm had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. During the same quarter last year, the business earned $1.32 earnings per share. Masimo’s revenue was down 11.0% compared to the same quarter last year. Equities analysts forecast that Masimo Co. will post 3.51 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.